索引于
- 打开 J 门
- Genamics 期刊搜索
- 学术钥匙
- 期刊目录
- 中国知网（CNKI）
- 乌尔里希的期刊目录
- 参考搜索
- 哈姆达大学
- 亚利桑那州EBSCO
- 期刊摘要索引目录
- OCLC-WorldCat
- 普布隆斯
- 日内瓦医学教育与研究基金会
- 欧洲酒吧
- 谷歌学术
分享此页面
期刊传单
抽象的
Complex Treatment of Multiple Sclerosis Patients by Use of Fetal Stem Cells
Nataliia Sergiyivna Sych, Mariya Klunnyk, Iryna Matiyashchuk, Mariya Demchuk, Olena Ivankova, Andriy Sinelnyk and Marina Skalozub
Objective: Refinement for all existing methods of treatment for the multiple sclerosis patients by means of combined method including conventional therapy and administration of fetal stem cells (FSCs)-suspensions containing stem cells derived from human fetal liver and brain.
Materials and methods: 51 patients diagnosed with MS participated in the study including 27 men and 24 women aged 27 to 56 years. Average age range for men was 34.2 ± 1.2 years, for women it constituted 31.7 ± 1.3 years. 33 patients were allocated in the Main Group (MG) including 20 men (mean age 29.8 ± 2.2 years) and 13 women (average age 31.3 ± 2.1 years). The Control Group (CG) was composed of 18 patients diagnosed with MSincluding 10 men (mean age of 30.5 ± 1.2 years) and 8 women (average age 31.4 ± 1.4 years). Simultaneously, the scale of MMSE was applied for objective study of cognitive functions among our patients. State Trait Anxiety Inventory was effective for emotional-anxiety disturbances. In addition, we assessed depression in patients by means of Beck Depression Inventory.
Results: Authors proved efficacy and safety of FSCs suspensions for MS patients. We emphasized a significant improvement of neurology deficit in the MG already over 6 months after fetal stem cells transplantation (FSCT), whereas the CG patients revealed such advantages over 12 months. Improvement of cognitive functions was characteristic for the MG starting from 6 months after FSCT. Anxiety and depression significantly decreased and these results were observed over 6 months after FSCT in the MG. In the CG, the same values which significantly decreased over 12 months after treatment and were recorded.
Conclusion: FSCs use in complex treatment of patients with MS stabilizes disease compensation, improves cognitive functions as well as psycho-emotional state of the patients.